Cover Image
市場調查報告書

主要已開發國家的胰臟癌治療藥市場:日益多樣化的市場形勢,強力的後期開發平台有希望

Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape

出版商 GBI Research 商品編碼 347860
出版日期 內容資訊 英文 138 Pages
訂單完成後即時交付
價格
Back to Top
主要已開發國家的胰臟癌治療藥市場:日益多樣化的市場形勢,強力的後期開發平台有希望 Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape
出版日期: 2015年12月01日 內容資訊: 英文 138 Pages
簡介

全球胰臟癌治療藥市場的收益2014年為17億4,600萬美元,預計2021年增加到29億2,000萬美元,以7.6%的年複合成長率成長。

本報告提供主要已開發國家的胰臟癌治療藥市場相關調查分析、市場概要、上市產品、開發中產品、市場預測、交易和策略性整合等相關的系統性資訊。

第1章 目錄

第2章 簡介

  • 疾病概要
  • 流行病學
  • 症狀
  • 危險因素
  • 病理生理學
  • 分期
  • 診斷
  • 疾病的預後
  • 治療流程

第3章 上市產品的商業性、臨床預測

  • 已經過核准產品
  • 仿單標示外的產品
  • 上市產品:考察

第4章 胰臟癌治療藥的開發平台

  • 概要:各階段,各分子類型
  • 概要:各分子標的
  • 臨床試驗
  • 開發平台上有前途藥物的候補
  • 開發平台的考察

第5章 市場預測

  • 全球市場
  • 北美
  • 歐洲5大市場
  • 日本

第6章 推動因素與阻礙

第7章 策略性整合

  • 主要的共同開發交易
  • 主要的授權交易

第8章 附錄

圖表

目錄
Product Code: GBIHC377MR

Executive Summary

Pancreatic Cancer (PC) is a disease predominately of the elderly with ~75% of PC cases being diagnosed in patient's over 75 years old. PC proliferates rapidly, is asymptomatic at its earliest stages and when symptoms do present themselves they are non-specific. There are currently no early detection methods in use for PC. Currently the best option for patient survival is resection which can triple five year survival rate to 15% compared to the unresectable stages of PC. Regrettably ~83% of patients present with advanced unresectable disease and patient prognosis is extremely poor. The majority of patients ultimately develop resistant disease, for whom treatment options have historically been limited, with treatment involving fluorouracil as a monotherapy or used in a combination therapy being standard. The recent approval of Onivyde for gemcitabine refractory disease in 2015 has improved survival of resistant patients, but there is a clear clinical need to diversify the treatment options for this patient cohort.

The current late-stage drugs in development for PC address this clinical need; however, results so far have been limited in their efficacy, with none demonstrating clinically transformative efficacy or safety. As a result, the growth in PC prevalence as a result of a global aging population, increasing diabetes and obesity prevalence is expected to be the key driver of this market throughout the forecast period.

Scope

Global revenues for the PC market are forecast to rise at a moderate CAGR of 7.6% from $1.746bn in 2014 to $2.92bn in 2021.

  • What factors are driving the market growth?
  • How can the factors limiting growth be overcome in the future?

The variation in mechanism of action has shifted away from the traditional chemotherapies, which dominate the marketed products, but account for only 7% of the pipeline. 44% of the pipeline are drugs inhibiting signal transduction.

  • What are the dynamics of the remaining 49% of the pipeline?
  • How does this reflect the need for novel targeted therapies?

Key mechanisms of action across the pipeline include cancer immunotherapies against IAP repeat containing proteins, whole cell vaccines and targeted therapies against the PI3K/Akt/mTOR pathway.

  • What is the scientific rationale behind these targets?

Several drugs are expected to be approved during the forecast period: TH-302, ruxolitinib phosphate, HyperAcute Pancreas, G17DT and clivatuzumab tetraxetan. However, their sales will be limited by their expected high costs.

  • Where will these novel therapies fit into the current treatment algorithm for PC?

The pipeline therapies, G17DT is expected to have the strongest performance, with revenues of $141m by 2021.

  • How will the other late stage pipeline drugs perform commercially?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis.
  • Visualize the composition of the pancreatic cancer market in terms of dominant molecule types and targets, highlighting the current unmet needs and how they can be addressed to allow a competitive understanding of gaps in the current market.
  • Analyze the pancreatic cancer pipeline and stratify by stage of development, molecule type, and molecular target.
  • Visualize the clinical safety and efficacy of late-stage pipeline drugs via a detailed heat map, outlining the results across major clinical trial endpoints.
  • Understand the growth in patient epidemiology, annual therapy costs, and market revenues for the pancreatic cancer market globally and across the US, UK, France, Germany, Italy, Spain, Japan, and Canada.
  • Identify commercial opportunities in the pancreatic cancer deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Epidemiology
  • 2.3. Symptoms
  • 2.4. Risk Factors
    • 2.4.1. Age
    • 2.4.2. Smoking
    • 2.4.3. Obesity
    • 2.4.4. Diet
    • 2.4.5. Inherited Mutations
    • 2.4.6. Chronic Pancreatitis
    • 2.4.7. Diabetes
    • 2.4.8. Infectious Diseases Risk Factors
    • 2.4.9. Precursor Lesions
  • 2.5. Pathophysiology
    • 2.5.1. Somatic Mutations
  • 2.6. Disease Stages
  • 2.7. Diagnosis
  • 2.8. Disease Prognosis
  • 2.9. Treatment Algorithm
    • 2.9.1. Adjuvant Therapy, Resected Cancer
    • 2.9.2. First-Line Treatment, Unresectable
    • 2.9.3. Second-Line Treatment, Unresectable

3. Commercial and Clinical Prospects of Marketed Products

  • 3.1. Approved Products
    • 3.1.1. Gemcitabine
    • 3.1.2. IV Fluorouracil
    • 3.1.3. Abraxane
    • 3.1.4. Tarceva
    • 3.1.5. Teysuno/TS-1/S-1
    • 3.1.6. Onivyde
  • 3.2. Off-Label Products
    • 3.2.1. Capecitabine
    • 3.2.2. Oxaliplatin
  • 3.3. Marketed Products - Discussion

4. Pipeline for Pancreatic Cancer Therapeutics

  • 4.1. Overview by Phase and Molecule Type
  • 4.2. Overview by Molecular Target
  • 4.3. Clinical Trials
    • 4.3.1. Clinical Trial Failure Rates
    • 4.3.2. Clinical Trial Duration
    • 4.3.3. Clinical Trial Size
    • 4.3.4. Discussion
  • 4.4. Promising Pipeline Molecules
    • 4.4.1. Evofosfamide (TH-302) - Threshold Pharmaceuticals.
    • 4.4.2. Tertomotide - Kael-GemVax
    • 4.4.3. Ruxolitinib phosphate - Incyte Corporation
    • 4.4.4. HyperAcute Pancreas/ Algenpantucel-L - NewLink Genetics Corporation
    • 4.4.5. G17DT - Cancer Advances
    • 4.4.6. Nimotuzumab - InnoMab
    • 4.4.7. Clivatuzumab Tetraxetan - Immunomedics.
  • 4.5. Pipeline Discussion

5. Market Forecast to 2021

  • 5.1. Global Market
  • 5.2. North America
    • 5.2.1. US
    • 5.2.2. Canada
  • 5.3. Top Five European Markets
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Treatment
    • 5.3.3. Market Size
    • 5.3.4. Japan

6. Drivers and Barriers

  • 6.1. Drivers
    • 6.1.1. Rising prevalence across all target markets
    • 6.1.2. Orphan Indication Incentives
    • 6.1.3. Growing Disease Awareness
    • 6.1.4. Better Diagnostics
    • 6.1.5. All Treatment Segments Have an Unmet Need
    • 6.1.6. High Number of Candidates in Late-Stage Drug Development
  • 6.2. Barriers
    • 6.2.1. Generics Will Restrict Premium Pricing
    • 6.2.2. High Failure Rates
    • 6.2.3. The High Genetic Heterogeneity of PC
    • 6.2.4. Typical Late Stage of Diagnosis

7. Strategic Consolidations

  • 7.1. Major Co-Development Deals
    • 7.1.1. Merck Serono Enters into Co-development Agreement with Threshold Pharma for TH-302
    • 7.1.2. GSK Enters into Co-development Agreement with OncoMed Pharmaceuticals for Novel Antibody Therapeutics
    • 7.1.3. OncoMed Pharma Enters into Co-development Agreement with Celgene Corporation for Anti-Cancer Stem Cell Therapies
  • 7.2. Major Licensing Deals
    • 7.2.1. Baxter International Enters into a Licensing Agreement with Onconova Therapeutics for Rigosertib
    • 7.2.2. Janssen Biotech Enters into Worldwide Licensing Agreement with Pharmacyclics for PCI-32765
    • 7.2.3. AVEO Pharmaceuticals Enters into a License and Development Agreement with Schering-Plough Corporation for AV-299
    • 7.2.4. Ardea Biosciences Enters Into a Licensing Agreement with Bayer HealthCare to Develop MEK Inhibitors

8. Appendix

  • 8.1. All Pipeline Drugs by Phase
    • 8.1.1. Discovery
    • 8.1.2. Preclinical
    • 8.1.3. Phase I
    • 8.1.4. Phase II
    • 8.1.5. Phase III
    • 8.1.6. Pre-Registration
  • 8.2. Market Forecasts to 2020
    • 8.2.1. Global
    • 8.2.2. The US
    • 8.2.3. Canada
    • 8.2.4. The UK
    • 8.2.5. France
    • 8.2.6. Germany
    • 8.2.7. Italy
    • 8.2.8. Spain
    • 8.2.9. Japan
  • 8.3. References
  • 8.4. Abbreviations
  • 8.5. Methodology
  • 8.6. Coverage
  • 8.7. Secondary Research
  • 8.8. Therapeutic Landscape
  • 8.9. Epidemiology-Based Forecasting
    • 8.9.1. Analogous Forecasting Methodology
  • 8.10. Market Size by Geography
    • 8.10.1. Forecasting Model for Therapeutic Areas
  • 8.11. Geographical Landscape
  • 8.12. Pipeline Analysis
  • 8.13. Competitive Landscape
  • 8.14. Contact Us
  • 8.15. Disclaimer

List of Tables

  • Table 1: Pancreatic Cancer Therapeutics, Symptoms and Causes
  • Table 2: Pancreatic Cancer Therapeutics, Inherited Mutation Information
  • Table 3: Pancreatic Cancer Therapeutics, Common Mutations in Pancreatic Cancer
  • Table 4: Pancreatic Cancer Therapeutics, TNM Classification System
  • Table 5: Pancreatic Cancer Therapeutics, Survival by Stage
  • Table 6: Pancreatic Cancer Therapeutics: Common Endpoints in Oncology Clinical Trials and their Description
  • Table 7: Pancreatic Cancer Therapeutics, Key Molecular Targets in the Pipeline
  • Table 8: Pancreatic Cancer Therapeutics, Global, Average Clinical Trial Duration (Months), 2015
  • Table 9: Pancreatic Cancer Therapeutics, Global, Cross Analysis of Clinical Trial Failure Rate, Duration and Size by Molecule Type or Mechanism of Action and Phase, 2006-2015
  • Table 10: Pancreatic Cancer Therapeutics, Efficacy of TH-302 & Gemcitabine Combination Therapy
  • Table 11: Pancreatic Cancer Therapeutics, Efficacy of Ruxolitinib & Capecitabine Combination Therapy
  • Table 12: Pancreatic Cancer Therapeutics, Top Five European Markets, Europe Age-Standardized Incidence Rates of Pancreatic Cancer (per 100,000), 2012
  • Table 13: Pancreatic Cancer Therapeutics, Top Five European Markets, Market Revenue Table ($m), 2014-2021
  • Table 14: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Discovery, 2015
  • Table 15: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Preclinical 2015
  • Table 16: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Phase I, 2015
  • Table 17: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Phase II, 2015
  • Table 18: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Phase III, 2015
  • Table 19: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Pre-Registration, 2015
  • Table 20: Pancreatic Cancer Market, Global, Market Forecasts, 2014-2021
  • Table 21: Pancreatic Cancer Market, The US, Market Forecasts, 2014-2021
  • Table 22: Pancreatic Cancer Market, Canada, Market Forecasts, 2014-2021
  • Table 23: Pancreatic Cancer Market, The UK, Market Forecasts, 2014-2021
  • Table 24: Pancreatic Cancer Market, France, Market Forecasts, 2014-2021
  • Table 25: Pancreatic Cancer Market, Germany, Market Forecasts, 2014-2021
  • Table 26: Pancreatic Cancer Market, Italy, Market Forecasts, 2014-2021
  • Table 27: Pancreatic Cancer Market, Spain, Market Forecasts, 2014-2021
  • Table 28: Pancreatic Cancer Market, Japan, Market Forecasts, 2014-2021
  • Table 29: Abbreviations

List of Figures

  • Figure 1: Pancreatic Cancer Therapeutics, Five-Year Survival by Age
  • Figure 2: Pancreatic Cancer Therapeutics, Efficacy and Safety Results for Key Parameters - Marketed Products, Adjuvant Therapies Post-Disease Resection
  • Figure 3: Pancreatic Cancer Therapeutics, Efficacy and Safety Results for Key Parameters - Marketed Products, First-Line Treatment Unresectable Disease
  • Figure 4: Pancreatic Cancer Therapeutics, Efficacy and Safety Results for Key Parameters - Marketed Products, Second-Line Treatment Unresectable Disease
  • Figure 5: Pancreatic Cancer Therapeutics, Global, Pipeline by Stage of Development, Molecule Type and Program Type
  • Figure 6: Pancreatic Cancer Therapeutics, Global, Pipeline by Mechanism of Action, 2015
  • Figure 7: Pancreatic Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of Development, 2015
  • Figure 8: Pancreatic Cancer Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2015
  • Figure 9: Pancreatic Cancer Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2015
  • Figure 10: Pancreatic Cancer Therapeutics, Global, Clinical Trial Failure Rate by Mechanism of Action, 2006-2015
  • Figure 11: Pancreatic Cancer Therapeutics, Global, Clinical Trial Duration by Phase and Molecule Type, 2006-2015
  • Figure 12: Pancreatic Cancer Therapeutics, Global, Clinical Trial Duration by Phase and Mechanism of Action, 2006-2015
  • Figure 13: Pancreatic Cancer Therapeutics, Global, Clinical Trial Size by Molecule Type, 2006-2015
  • Figure 14: Pancreatic Cancer Therapeutics, Global, Clinical Trial Size by Mechanism of Action, 2006-2015
  • Figure 15: Pancreatic Cancer Therapeutics, Global, Cumulative Clinical Trial Size by Molecule Type, 2006-2015
  • Figure 16: Pancreatic Cancer Therapeutics, Global, Cumulative Clinical Trial Size by Mechanism of Action, 2006-2015
  • Figure 17: Pancreatic Cancer Therapeutics, Global, Estimated Sales of TH-302 ($m), 2019-2021
  • Figure 18: Pancreatic Cancer Therapeutics, Global, Estimated Sales of Ruxolitinib Phosphate ($m), 2018-2021
  • Figure 19: Pancreatic Cancer Therapeutics, Global, Estimated Sales of HyperAcute Pancreas ($m), 2019-2021
  • Figure 20: Pancreatic Cancer Therapeutics, Global, Estimated Sales of G17DT ($m), 2018-2021
  • Figure 21: Pancreatic Cancer Therapeutics, Global, Estimated Sales of Clivatuzumab Tetraxetan ($m), 2019-2021
  • Figure 22: Pancreatic Cancer Therapeutics, Efficacy and Safety Results for Key Parameters - Pipeline and Marketed Products (Light Blue), Adjuvant Therapies Post-Disease Resection
  • Figure 23: Pancreatic Cancer Therapeutics, Efficacy and Safety Results for Key Parameters - Pipeline and Marketed Products (Light Blue), First-Line Treatment of Unresectable Disease
  • Figure 24: Pancreatic Cancer Therapeutics, Efficacy and Safety Results for Key Parameters - Pipeline and Marketed Products (Light Blue), Second-Line Treatment of Unresectable Disease
  • Figure 25: Pancreatic Cancer Therapeutics, Product Competitiveness Framework in Metastatic Disease
  • Figure 26: Pancreatic Cancer Therapeutics Market, Global, Treatment Usage Patterns ('000 patients) and Market Revenues ($m), 2014-2021
  • Figure 27: Pancreatic Cancer Therapeutics, US, Treatment Usage Patterns ('000 patients) and Annual Cost of Therapy ($), 2014-2021
  • Figure 28: Pancreatic Cancer Therapeutics Market, US, Market Revenues ($m), 2014-2021
  • Figure 29: Pancreatic Cancer Therapeutics, Canada, Treatment Usage Patterns ('000 patients) and Annual Cost of Therapy ($), 2014-2021
  • Figure 30: Pancreatic Cancer Therapeutics Market, Canada, Market Revenues ($m), 2014-2021
  • Figure 31: Pancreatic Cancer Therapeutics, Top Five European Markets, Treatment Usage Patterns ('000 patients), 2014-2021
  • Figure 32: Pancreatic Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2014-2021
  • Figure 33: Pancreatic Cancer Therapeutics, Top Five European Markets, Market Size ($m), 2014-2021
  • Figure 34: Pancreatic Cancer Therapeutics, Japan, Treatment Usage Patterns ('000) and Annual Cost of Therapy ($), 2014-2021
  • Figure 35: Pancreatic Cancer Therapeutics, Japan, Market Size ($m), 2014-2021
  • Figure 36: Pancreatic Cancer Therapeutics, Global, Co-Development Deals by Region, Value ($m), Year and by Phase, 2006-2014
  • Figure 37: Pancreatic Cancer Therapeutics, Global, Co-Development Deals by Molecule Type and Mechanism of Action 2006-2014
  • Figure 38: Pancreatic Cancer Therapeutics, Global, Licensing Deals by Region, Value ($m), Year and by Phase, 2006-2014
  • Figure 39: Pancreatic Cancer Therapeutics, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2014
  • Figure 40: GBI Research Market Forecasting Model
Back to Top